NTL HEALTHCARE Pushes CerviCARE AI Into South Africa After WHX Johannesburg
South Korean company NTL HEALTHCARE says more than 200 representatives visited its booth at WHX Johannesburg 2026, where it presented its AI-powered cervical screening system, CerviCARE AI. The company plans to use South Africa as a strategic hub for wider African expansion.
- NTL HEALTHCARE showed CerviCARE AI at WHX Johannesburg 2026 from October 6 to 8, with 200+ visitors at its booth.
- The company supplied its product to Zimbabwe during the exhibition.
- It plans to make South Africa a strategic hub, building on pilots in Zambia, Uganda and Tanzania.
- According to the company, CerviCARE AI returns results within five seconds offline, with 98% sensitivity and 95.5% specificity for high-risk lesions.
- NTL HEALTHCARE says it has supplied CerviCARE AI to 20+ countries.
Talks with distributors, institutions and policymakers
NTL HEALTHCARE showed CerviCARE AI at WHX Johannesburg 2026 in South Africa from October 6 to 8. According to the company, more than 200 representatives from distributors, healthcare institutions and policy organizations came to the booth to learn about the technology and explore possible partnerships.
The company says the event was more than product promotion. It met South African policymakers and academic representatives to discuss implementation procedures and potential collaborations, which it describes as groundwork for local adoption and commercialization.
During the exhibition, NTL HEALTHCARE also supplied its product to Zimbabwe, which it presents as further progress in its regional expansion.
South Africa as a hub for the region
NTL HEALTHCARE builds on pilot projects in Zambia, Uganda and Tanzania. It plans to make South Africa a strategic hub for reaching neighboring countries and other African markets.
The company intends to pursue opportunities through partnerships with global medical foundations and through Korea's Knowledge Sharing Program (KSP), a government initiative that promotes knowledge sharing in the field of economic development. It says it aims to develop healthcare collaboration models tailored to local needs and to work with partners on regulatory approvals, training and operational planning.
Tae-hee Kim, CEO of NTL HEALTHCARE, said: "Screening technologies need practical validation and policy support to become established in healthcare settings." She added that the company had discussed implementation procedures and partnership opportunities with South African stakeholders, building on its pilot experience.
What CerviCARE AI does
CerviCARE AI analyzes cervical images to identify potential lesions. According to the company, it delivers results within five seconds without an internet connection. It also offers AI-assisted image quality guidance, which is meant to help users capture consistent, high-quality images regardless of their level of experience.
NTL HEALTHCARE cites 98% sensitivity and 95.5% specificity in detecting high-risk lesions. It attributes these figures to a StandardBank test report (2023) and a study by Ouh et al. published in Scientific Reports (2024).
Why the African market matters
The company points to the burden of cervical cancer on the continent. Citing the World Health Organization (WHO, 2026), it says cervical cancer is the leading cause of cancer deaths among women in 26 countries, many of them in sub-Saharan Africa. Unequal access to vaccination, screening and treatment remains a major challenge, which in the company's view underlines the need for technologies that support timely and consistent screening in resource-limited settings.
Founded in 1996, NTL HEALTHCARE says it has supplied CerviCARE AI to 20+ countries. It plans to expand product distribution and partnerships across Africa. The announcement describes discussions and plans rather than finalized adoption agreements in South Africa, so the next steps will depend on regulatory approvals and the partnerships the company seeks.
